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Abstract
Background: Germ-line mutations in the BRCA1 and BRCA2 genes are major contributors to hereditary breast/
ovarian cancer. Large rearrangements are less frequent in the BRCA2 gene than in BRCA1. We report, here, the first
total deletion of exon 3 in the BRCA2 gene that was detected during screening of 2058 index cases from breast/
ovarian cancer families for BRCA2 large rearrangements. Deletion of exon 3, which is in phase, does not alter the
reading frame. Low levels of alternative transcripts lacking exon 3 (Δ3 delta3 transcript) have been reported in
normal tissues, which raises the question whether deletion of exon 3 is pathogenic.
Methods: Large BRCA2 rearrangements were analysed by QMPSF (Quantitative Multiplex PCR of Short Fluorescent
Fragments) or MLPA (Multiplex Ligation-Dependent Probe Amplification). The exon 3 deletion was characterized with a
“zoom-in” dedicated CGH array to the BRCA2 gene and sequencing. To determine the effect of exon 3 deletion and
assess its pathogenic effect, three methods of transcript quantification were used: fragment analysis of FAM-labelled
PCR products, specific allelic expression using an intron 2 polymorphism and competitive quantitative RT-PCR.
Results: Large rearrangements of BRCA2 were detected in six index cases out of 2058 tested (3% of all deleterious
BRCA2 mutations). This study reports the first large rearrangement of the BRCA2 gene that includes all of exon 3
and leads to an in frame deletion of exon 3 at the transcriptional level. Thirty five variants in exon 3 and junction
regions of BRCA2 are also reported, that contribute to the interpretation of the pathogenicity of the deletion. The
quantitative approaches showed that there are three classes of delta3 BRCA2 transcripts (low, moderate and
exclusive). Exclusive expression of the delta3 transcript by the mutant allele and segregation data provide evidence
for a causal effect of the exon 3 deletion.
Conclusion: This paper highlights that large rearrangements and total deletion of exon 3 in the BRCA2 gene could
contribute to hereditary breast and/or ovarian cancer. In addition, our findings suggest that, to interpret the pathogenic
effect of any variants of exon 3, both accurate transcript quantification and co-segregation analysis are required.
Background
The BRCA2 gene (MIM#600185) is a tumour suppressor
gene that codes for a 3,418 amino-acid protein. It is
involved in DNA damage repair through homologous
recombination, chromatin remodelling and regulation of
transcription [1]. All of these functions are important
for the maintenance of genome integrity. Germ-line
mutations in the BRCA2 gene predispose to high risk of
breast and ovarian cancer (BOC). Mean cumulative risks
for breast and ovarian cancer in BRCA2 mutation car-
riers are 49% and less than 20% at 70 years of age,
respectively [2].
Genetic testing is now performed in routine for
women with severe family histories of breast and ovar-
ian cancer, in order to identify deleterious mutations in
the two susceptibility genes, BRCA1 and BRCA2.P o i n t
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on the inclusion criteria. Tests for BRCA1 gene rearran-
gements have been added recently, as large rearrange-
ments contribute to ~10% of the BRCA1 mutations
detected. In contrast to the BRCA1 gene, reports of
large rearrangements in the BRCA2 gene are rare. Up to
now, seven large rearrangements of BRCA2 have been
described in France [3].
In our two French Medical Centres (St Cloud and
Strasbourg), a retrospective screening for large rearran-
gements in the BRCA2 gene on 2058 index cases that
lacked BRCA1-2 point mutations, led to the identifica-
tion of five out-of-frame large rearrangements. Addi-
tionally, for the first time, a novel large rearrangement
in the BRCA2 gene (Δ3 LR) that leads to a complete in
frame deletion of exon 3 has been identified. The patho-
genicity of exon 3 deletion is questionable. Exon 3 with
249 bp is in phase, similar to exons 10, 11, 12, 19 and
26, and therefore, deletion does not alter the reading
frame and the functionally important amino-terminal
BRCA2 region. The functional role of the affected pro-
tein exon 3 domain is not yet fully established and more
striking, a physiological alternative transcript that lacks
exon 3 (Δ3 delta3-transcript) has been described [4].
We report also here all of the variants of exon 3 and
surrounding introns that were identified in 2461 index
cases screened for germ-line mutations in both BRCA1
and BRCA2. Analysis of the transcripts of some of these
variants is informative about the potential pathogenicity
of exon 3 deletion. Finally, we propose three technical
approaches that would contribute to a better under-
standing of the impact of variants on exon 3 skipping.
Methods
Probands
Genetic testing was offered to high-risk individuals
according to criteria designed by the French national
Group “Genetique et Cancer” (GGC) and Inserm
recommendations [5]. Blood samples were collected fol-
lowing informed consent for participation in testing and
subsequent research studies. The study was performed
in the diagnostic context. The informed consent form
was written and approved by a local medical ethical
committee in accordance with guidelines from the
French national group “Genetique et Cancer”. A conse-
cutive series of 2461 index cases (probands) were ana-
lyzed from 1996 to 2009 in our two French Medical
Centres (Centre Paul Strauss, Strasbourg and Institut
Curie-Hospital René Huguenin, St Cloud-Paris). We
report here all of the variants identified in exon 3 of the
BRCA2 gene. Large rearrangements in the BRCA2 gene
were studied retrospectively in 2058 consecutive index
cases that were found to be non informative (without
any deleterious variant) after conventional BRCA1/
BRCA2 mutation screening and BRCA1 large rearrange-
ment analysis by MLPA.
Semi-quantitative experiments were performed on
RNA derived from blood samples or lymphoblastoid cell
lines (LBC) of index cases with mutations in BRCA2
exon 3 and surrounding introns. These included: in
intron 2, c.68-7T>A variant (four proband samples),
c.68-7delT (one proband sample) and c.68-7_8delinsAA
(one proband sample); in exon 3, five patient samples
carrying respectively the nonsense mutations c.71T>A (p.
Leu24X), c.244A>T (p.Lys82X) and c.250C>T (p.
Gln84X) and the missense variants c.125A>G (p.
Tyr42Cys) and c.223G>C (p.Ala75Pro); in intron 3, one
proband carrier of the c.316+3delA mutation. Eighteen
control RNA samples, consisting of “PAXgene blood” (8
samples) and lymphoblastoid cell RNA (10 samples) from
individuals screened non informative (without any dele-
terious variants) for BRCA1/BRCA2 genes were used.
To evaluate the proportion of delta3-transcripts in
breast tumour tissues, cDNA samples from 185 sporadic
invasive ductal breast carcinomas were analyzed. cDNA
from three head and neck (HN) cancer tissues and three
matched normal HN tissues were also analyzed to deter-
mine if this alternative transcript could be unbalanced in
other tumour tissue types.
BRCA2 large rearrangement screening
Large rearrangements (LRs) of the BRCA2 gene were
investigated with two techniques: QMPSF assay (Quanti-
tative Multiplex PCR of Short Fluorescent Fragments)
using the conditions described by Tournier et al. [6,7]
or MLPA (Multiplex Ligation-Dependent Probe Amplifi-
cation) using the SALSA P045 BRCA2 MLPA kit (MRC
Holland, the Netherlands) [8]. Results were evaluated by
cumulative comparison of the samples with three nor-
mal control samples, after normalization relative to the
peaks of the control gene and the control samples. All
abnormal observation was confirmed with a second
“alternative” technique and on a second independent
blood sample from the patient.
Characterization of the exon 3 large rearrangement
Zoom-in dedicated CGH array
To confirm and characterize large rearrangements of the
BRCA2 gene, a zoom-in dedicated CGH-array was
applied. An 11 kb-oligonucleotide microarray was spe-
cially designed using oligonucleotides designed in house
and with validated oligonucleotides from Agilent (Agi-
lent technology, USA), as described [9]. Of these, 9294
were located throughout the genome (4339 Agilent oli-
gonucleotides and 3107 BRCA1 in-house oligonucleo-
tides). The remaining 2749 oligonucleotides were
specifically designed for the BRCA2 gene and its flank-
ing regions. The region covered by the oligonucleotides
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Page 2 of 12was from 31,718,050 to 31,950,008 (Hg18, Human gen-
ome assembly 18). In the 5’ region, there were 956 oli-
gonucleotides that cover 70 kb. In the coding region,
there were 1167 oligonucleotides that cover 84 kb. In
the 3’ region, there were 626 oligonucleotides that cover
78 kb. The analytical approach has been described else-
where [9]. For the interpretation of the oligonucleotide
signal, the threshold chosen was deleted if the log2 ratio
w a s<- 0 . 4a n dd u p l i c a t e di f>0 . 4 .T h el o g 2r a t i ow a s
normalized as described in [9].
DNA breakpoints analysis
The breakpoints were characterized by long-range PCR
of genomic DNA using the Qiagen Long-Range PCR kit
(Qiagen, Germany). 150 ng of DNA was amplified with
a primer pair that tightly flanks the respective break-
point regions identified by the CGH-array in a reaction
volume of 25 μl (Table 1). PCR products were subse-
quently fractionated through 1% agarose gels. The bands
were purified with the QIAquick gel extraction kit (Qia-
gen, Germany), and sequenced with the same primers
using the Big Dye terminator cycle sequencing reaction
kit and an ABI-3130XL genetic analyser (Applied Bio-
systems, France).
Transcript Analysis
Depending on the availability of the material, total RNA
was extracted either from blood samples collected in
PAXgene Blood RNA tubes, using the PAXgene kit
according to the manufacturer’s protocols (Preanalitix,
Qiagen, Germany) or from lymphoblastoid cell lines
(LBC) using the acid-phenol guanidinium method with
RNA-BTM solution (Eurobio, France).
An ubiquitous alternative transcript lacking exon 3
has already been described [4 ]b u ts u b s e q u e n td a t ao n
expression of this alternative transcript was discrepant
[10-12]. In order to determine the effect of the Δ3
BRCA2 rearrangement and assess its pathogenic effect,
we used three methods of quantification.
1) Fragment analysis: exon specific RT-PCR was per-
formed with the Qiagen Onestep PCR kit as recom-
mended (Qiagen, France) with a set of FAM-labelled
primers spanning exon 2 to 6 and exon 2 to exon 10
(Table 1) for 25 cycles and including 200 ng RNA in 25
μl reaction volume. The products were analyzed with
fragment analysis software after separation on a ABI-
3130XL genetic analyser (Applied Biosystems, France).
The experiments were performed in triplicate. This
technique detects low levels of products and gives a
semi-quantitative evaluation of the PCR products. Peak
heights corresponding to exon exclusion and wild type
transcript were measured and the proportion of the
delta3-transcript was expressed as a percentage of the
total amount of transcripts.
Table 1 Oligonucleotide primers used for the exon 3 large rearrangement and transcript analysis
BRCA2 Primers Nucleotide sequence Size of PCR products PCR temperature
Breakpoint analysis
C2del3-F2 5’_CAAGATCACTTCATTGATTTGTGAG_3’ 4572 bp 59°C
C2del3-R2 5’_CGCTATATTTCTGTGTGCCTTTAAT_3’
Transcript analysis
Fragment analysis
Exon 02-06 480 bp 56°C
Rc2-01-F2 5 ‘6FAM_GATCCAAAGAGAGGCCAAC_3’
Rc2-06-R 5’_CAAACTCCCACATACCACTGA_3’
Exon 02-10 1350 bp 56°C
Rc2-01-F2 5’ 6FAM _GATCCAAAGAGAGGCCAAC_3’
Rc2-10R 5’_TGGTAGGCTAGAAATACGTGGC_3’
Pyrosequencing
Allelic expression of c.-26G > A
Ex1-2 F TACTCCGGCCAAAAAAGAACTGCA
Ex2-Ex2/4 R TATGTCTACTATTGGGAACATTCCTTCCTG 166 pb 55°C
Ex2-Ex3/4 R ATTGGGAACATTCCTTCCTAAGTCTA 411 pb 55°C
Ex2 R GATCCAATAGGCATTTTTACCTACGATATTCC 89 pb 55°C
Ex2 SEQ R TACCTACGATATTCCTCCAATG
Competitive quantitative PCR
EX2 Cpcr F TGAAATTTTTAAGACACGCTGCAACA 60°C
EX2/3 Cpcr R AAACCAATTAAGACTTATTGGTCCTAAATCT 59 bp 60°C
EX2/4 Cpcr R ACTATTGGGAACATTCCTTCCTGCT 47 bp 60°C
EX2 Cpcr SEQ F TTAAGACACGCTGCAA
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Page 3 of 122) Allelic expression: allelic specific expression was
evaluated by pyrosequencing with a PyroMark Q96 ID
(Qiagen, France) with cDNA samples isolated from indi-
viduals who are heterozygous for the 5’UTR variant c.-
26 G>A in exon 2 of the BRCA2 gene. This polymorph-
ism is well documented and is called rs1799943 (37% of
heterozygosity). Three sets of primers were used (Table
1): exon 2 to the junction between exons 3 and 4 (Ex2-
Ex3/4) for the full-length transcript, exon 2 to the junc-
tion between exons 2 and 4 (Ex2-Ex2/4) for the delta3-
transcript, and only on exon 2 for all transcripts. The
proportion (%) of each allele was estimated for samples
that are heterozygous for the c.-26 G>A variant by pyro-
sequencing using the EX2-SEQ primer. The heterozyg-
osity was validated with the complete set of primers for
all the transcripts. The robustness of this approach was
validated with 10 control wild type samples; equivalent
expression of each allele should result in a 50%/50%
ratio, whatever the primer set used. For missense or
nonsense mutations in the exon, the allelic expression
of the specific heterozygous variant was also studied
when the sample was not heterozygous for the c.-26
G>A (primer sequences on demand).
3) Competitive quantitative RT-PCR (Additional file 1):
a competitive quantitative RT-PCR (C-QPCR) was set to
detect imbalances of expression between the delta3 and
full-length transcripts. The common forward primer
(EX2 Cpcr F) was complementary to exon 2, the reverse
primers were complementary to the exon2-exon3 junc-
tion (EX2/3 Cpcr R for the full-length transcript) and the
exon2-exon4 junction (EX2/4 Cpcr R for the delta3-tran-
script) (Table 1). The primer mix contained 0.16 μM
EX2 Cpcr F, 0.4 μME X 2 / 3C p c rRa n d0 . 1 6μME X 2 / 4
Cpcr R. These concentrations compensated for differ-
ences in the efficiencies of the PCR. Serial dilutions of
mixtures of the two templates (delta3 and full-length)
were used to validate the quantitation (Additional file
1c). The concentration was assessed by pyrosequencing
with a PyroMark Q96 ID (Qiagen, France). The sequen-
cing primer, EX2 Cpcr SEQ, is close to the exon2-exon3
junction, and the pyrosequencing sequence is CAGAT
(Additional file 1a). The sequence of the full-length tran-
script is CAGAT and the delta3-transcript CAGGA with-
out a T. The measurement of the proportion of delta3-
and full-length transcript was done on the GA which is
one for each nucleotide in the full-length transcript and
two for each nucleotide in the delta3-transcript. The last
T was a marker whose value is three in the full-length
transcript and null in the delta3-transcript. cDNA sam-
ples from 96 lymphoblastoid cell lines from patients
without mutations in exon 3 and intronic regions were
used to validate the approach. The proportion of the
delta3-transcript in the controls was 4% +/- 5%. All
experiments were performed in triplicate.
Human Genetic Variation Society (HGVS) guidelines
were followed for the nomenclature of BRCA2.T h e
genomic positions correspond to the Human Genome
18/build 36 (2006). GenBank accession number used
was NM_000059.3 and NP_000050.1 for cDNA and
amino acid numbering respectively. The A of the ATG
translation initiation codon is + 1.
Results
Point mutations in exon 3
Among the 2461 index cases analysed in the two Medi-
cal Centres, 35 variants were identified in exon 3. There
were 5 nonsense mutations: c.71 T>A, (p.Leu24X),
c.172G>T (p.Glu58X), c.244A>T (p.Lys82X), c.250C>T
(p.Gln84X), c.273C > G (p.Tyr91X), and one deletion
with a frameshift c.488_489del (p.Ser163IlefsX19). There
were also several missense variants of unknown signifi-
cance: nine c.125A > G (p.Tyr42Cys), one c.179A > G
(p.Asn60Ser), three c.223G > C (p.Ala75Pro), one
c.266C > T (p.Pro89Leu). In intron 2, there were nine
c.68-7T > A, one c.68-7delT and one c.68-7_8delinsAA.
In intron 3, there were 4 variants: c.316+3delA, c.316
+5G > C, c.316+9T > A and c.316+33C > G. Unfortu-
nately, RNA was only available for these variants: c.316
+3delA, c.125A > G, c.223G > C, c.71T > A, c.244A >
T, c.250C > T, c.68-7T > A, c.68-7delT, c.68-
7_8delinsAA.
Large rearrangement screening
Among the 2461 index patients, 2058 were analysed for
large rearrangements in the BRCA2 gene by QMPSF
and/or MLPA. Six large rearrangements were detected
in the BRCA2 gene: one deletion of exon 3 (family with
six breast cancers cases), two deletions of exons 15 and
16 (family with five breast cancer cases and in a breast/
ovarian cancer family), one deletion of exons 14 to 18
(family with four breast cancer cases), one deletion of
exons 22 to 27 (family with two breast cancer cases)
and one duplication of exons 17 to 20 (breast cancer
family). All, but the exon 3 deletion, led to frameshifts
that alter the coding capacities of the alleles.
Characterization of exon 3 deletion
Zoom-in dedicated CGH-array to the BRCA2 gene
described the deleted region to measure from 3.6 to 6.7
kb (Figure 1a). The breakpoints and precise size of the
deletion were established byl o n g - r a n g eP C R .T h ep r i -
mer set used gave rise to the expected normal PCR pro-
duct of 4,572 bp in the control DNA. In the mutant
DNA, a lower product of approximately 500 bp was
observed in addition to the normal PCR product.
Sequencing of the lower PCR product (Figure 1b)
showed that the deletion spans 4,063 bp and includes
925 bp of intron 2, the entire exon 3 (249 bp) and 2,889
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described as g.31.790.289_31.794.351del, and the dele-
tion c.68-925_316+2889del, p.Asp23_Leu105del.
Two repeat elements around this deletion were
reported. In the 5’ region, there is a 735-bp sequence
that is called Charlie 1a, type MER1, and in the 3’
region a 313-bp sequence called L1MC2, LINE type. We
did not detect any similarities in these two regions,
either 1000-bp around the breakpoint or 1500-bp within
the deletion.
In the proband RNA sample carrying exon 3 deletion,
Onestep RT-PCR with primers spanning exons 2 to 6
gave two PCR products: the expected wild type product
of around 480 bp and a lower sized product of ~ 200
bp. Both bands were of similar intensity. Sequencing of
the smaller PCR product showed that it contains an in
frame deletion of exon 3. Thus, the large genomic rear-
rangement Δ3-LR results in a stable delta3-transcript.
Transcript analysis
In order to determine the effect of the Δ3-LR alteration
and assess its pathogenic effect, semi-quantitative
experiments were performed on various RNA samples.
Three approaches were necessary to obtain unambigu-
ous results and to determine the effects of sequence var-
iants on delta3-transcript expression.
Semi-quantitative fragment analysis of Onestep PCR
products spanning exons 2 to 6 was necessary, since
products fractionated on agarose gels do not give reli-
able results. In particular, the abnormal shorter PCR
product, corresponding to the delta3-transcript, was
very faint and not always detectable (Figure 2a). This
observation could explain why Machado et al. [11] and
Peixoto et al. [12] report discordant results. Fragment
analysis with a fluorophore on an automatic sequencer
gave reliable results, which were confirmed with PCR
products spanning exons 2 to 10 (data not shown). As
shown in Table 2 and Figure 2a, the proportion of the
delta3-transcript to the total transcript was variable
according to the type of variant. The “control samples”
(i.e. wild type or not mutated in exon 3), gave low levels
of the delta3-transcript that was, on average, less than
10% of the total transcript. In contrast, with samples
from cases carrying the Δ3-LR or the c.316+3delA, the
PCR products corresponding to the delta3-transcript
corresponded to 61% and 52% of the total. Samples
with nucleotide variants in intron 2 also had increased
levels of the delta3-transcript, which proportions ran-
ging from 14% to 52% of the total. Heterogeneity within
samples carrying the same variant was also observed.
The discrepancy for c.68-7T>A could be associated with
t h en a t u r ea n dq u a l i t yo ft h ec D N Af r o ml y m p h o b l a s -
toid cells (52% and 45%) or from PaxGene extraction
(14% and 23%). Samples with nonsense mutations in
exon 3 gave a level that was similar to control samples,
with a range between 5% and 12%. The results were
similar when samples were treated with puromycin.
Thus, two classes of expression were detected, with low
or high levels of delta3-transcripts. In this approach,
competition in the PCR between the two amplicons
with different sizes could result in preferential amplifi-
cation of the lower sized delta3-transcript. To circum-
vent this problem, we developed two alternative
methods: allele-specific RT-PCR and competitive quan-
titative RT-PCR (C-QPCR) combined with
pyrosequencing.
BRCA2
Exon 3
Intron 3 Intron 2
c.316+2889 c.68-925
4063 bp
Allele 1
Allele 2
ab
Figure 1 Genomic analysis of the Δ3 BRCA2 large rearrangement.a :Dedicated BRCA2 CGH array. The gene is represented at the top, with
vertical boxes that indicate exon positions and sizes. Black plots are considered to be within the diploidy range (the y axis gives the log2
intensity ratios). The green dots indicate signals that were below the threshold for deletion (-0.4 log2 ratio). b: Sequence analysis of the smaller
PCR product obtained by long-range PCR of proband DNA with the exon 3 large rearrangement in BRCA2 (Hg18/build36, 2006). The sequence
crosses the breakpoint that begins in intron 2 and ends in intron 3.
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Page 5 of 12Some of the samples that are heterozygote for the c.-
26 G>A polymorphism of the BRCA2 gene were ana-
lyzed by pyrosequencing, to determine the proportion of
transcripts that come from each allele (allelic discrimi-
nation) and quantify the relative proportion of delta3-
transcript (Table 2 Figure 2b and Additional file 2). For
wild-type samples (c.-26 G>A heterozygous), as
expected, the percentage of G and A alleles was close to
50%, whatever the primer set used. For example, with
the primer that spans the exon 3-4 junction, the average
was 48% A and 52% G, with a standard deviation of 4%.
Significantly, for the c.316+3delA, one allele expressed
the full-length transcript and the other the delta3-tran-
script, suggesting exclusive expression of the delta3-
transcript from the mutant allele. Unfortunately, there
were no c.-26 G>A polymorphism in carriers of the Δ3-
LR. By definition, the allele with the Δ3-LR cannot
express the full-length transcript. This sample was then
used as a reference. For variants in intron 2, the percen-
tages of the A (or G) and G (or A) allele were 30% and
70%, respectively, using sets of primers specific to the
delta3- and full-length transcript, whereas they were
ATCTCGT AT A
ATCTCGTATA
GCAGAT
c
.
3
1
6
+
3
d
e
l
A
c
.
6
8
-
7
T
>
A
W
i
l
d
-
t
y
p
e
GCAGAT
GCAGAT
Delta3 : 20%
Delta3 : 46%
Delta3 : 5%
TTTGGTAAATA
CTTGGTAAATA
30%
70%
TTTGGTAAATA
CTTGGTAAATA
0%
100%
ATCTCGTATA
TTTGGTAAATA
CTTGGTAAATA
52%
48%
ab c
477bp 231bp
477bp 231bp
477bp 231bp
Figure 2 Analysis of delta3-transcript expression.a :Fragment analysis of Onestep RT-PCR products spanning exon 2 to 6. Semi-quantitative
fragment analysis of Onestep RT-PCR products revealed the presence of the wild type transcripts at 477 bp and the delta3 alternative transcripts
at 231 bp, as shown in the electrophoretograms of a control sample (wild type) and samples with the c.68-7T>A and c.316+3delA mutations.
The percentages of delta3-transcript were, respectively: 6%, 22% and 61% for the sample illustrated. Left upper panels: agarose gel images of the
same products after 33 cycles of PCR; the left wells contain the control, the right wells the samples with the respective mutation. b:
Pyrosequencing histogram from the pyrogram for the c.-26A>G polymorphism with the primer set Ex1-2 F and Ex2-Ex3/4 R (only the full-length
transcript). The sequence is C/T TTGGTAAATA. The proportion of C and T is directly computed by the pyrosequencing software. c: Pyrosequencing
histogram from the pyrogram for the competitive QPCR using primer set exon 2/exon 3 and exon 2/exon 4 for the full-length transcript and
delta3-transcripts, respectively. The sequence of the exon 2/3 transcript is CAGATTT and the sequence of the exon 2/4 transcript is CAGGAA. The
proportion of GA (full-length transcript) and GGA (delta3-transcript) is directly computed on the pyrosequencing software.
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Page 6 of 1250%-50% with the set of primers for all transcripts, sug-
gesting that there is an imbalance in favour of the
delta3-transcript. The allelic discrimination was quanti-
fied also with variants other than c.-26 G>A, including
c.71T>A (p.Leu24X), c.125A>G (p.Tyr42Cys), c.223G >
C (p.Ala75Pro), c.244A > T (p.Lys82X), c.250C > T (p.
G l n 8 4 X )w i t h i ne x o n3 .F o rt h em i s s e n s ev a r i a n t s
[c.125A > G (p.Tyr42Cys) and c.223G > C (p.Ala75Pro)],
the quantification gave a balanced proportion of A and
G (47-53%) and G and C (50-50%) respectively (Table
2). For the nonsense variants [c.71T>A (p.Leu24X),
c.244A>T, (p.Lys82X) and c.250C>T (p.Gln84X)], the
results were comparable to wild-type, (50% for each
allele). Puromycin treatment did not change the results,
suggesting that nonsense mediated mRNA decay (NMD)
is not involved.
Competitive quantitative RT-PCR (C-QPCR) analysis
confirmed the results from fragment analysis. Due to
the higher sensitivity of this method, the results appear
to be more reliable. The values were globally lower than
by fragment analysis, and could differentiate between
three classes of delta3-transcript levels (Table 2, Figure
2c and Additional file 1). For wild-type samples, the
proportion of delta3-transcript was close to 4%. As in
fragment analysis, the ratio between delta3- and full-
length transcripts was significantly higher, close to 40%,
for both mutations leading to exclusive deletion of exon
3. For intronic variants in intron 2, the proportion was
intermediate, close to 25%. There is less disparity within
samples, compared to fragment analysis. For the mis-
sense variants, c.125A>G (p.Tyr42Cys) and c.223G>C
(p.Ala75Pro), the proportion was similar to wild type,
3% and 5%, respectively. For the nonsense variants, the
proportion ranged from 2 to 10%, consequently they
can be included to the class with low levels of delta3-
transcript expression.
On 185 sporadic breast cancer samples, C-QPCR gave
l o w( <1 0 % )t on od e t e c t a b l ee x p r e s s i o no ft h ed e l t a 3 -
transcript, except for seven samples (4% of samples ana-
lysed). The increases of delta3-transcripts were 10-15%
in four samples, 15-20% in 2 samples and about 45% in
one. This latter sample, with significant expression of
delta3-transcript, came from an inflammatory triple
negative breast cancer (0.5% in the samples analysed).
Constitutional analysis could not be performed, to
determine the BRCA1/2 status of the patient.
Co-segregation analysis
To determine whether the exon 3 deletion co-segregates
with cancer, we examined the occurrence of this allele
in members of the family A-2005 with the Δ3-LR and of
the family B-2002 with the c.316+3delA mutation.
Family A-2005 (Figure 3) had a breast cancer family
history with 6 assessed breast cancer cases. Four of
Table 2 Analysis of delta3-transcript expression by fragment analysis, allele specific PCR on c.26 G>A heterozygous
samples and competitive quantitative C-QPCR
Fragment analysis
% delta3-transcript
/total transcripts
(± standard deviation)
Allelic discrimination
Exclusively on exon3 full-length transcript
(± standard deviation)
Competitive QPCR
% delta3-transcript
/full-length transcript
(± standard deviation)
A allele B allele
Wild-type (10 samples) 8 ± 2% * 48 ± 4%A 52%G 4 ± 2%
c.316+3delA 52 ± 7%# 0% A 100%G** 44 ± 4%
Delta3 BRCA2 rearrangement 61 ± 3%# - - 44 ± 7%
Intron 2 variants
c.68-7T>A 14 ± 2%# - - 31 ± 10%
c.68-7T>A 23 ± 4%# - - 25 ± 4%
c.68-7T>A 52 ± 2% 27 ± 6%A 73%G 23 ± 3%
c.68-7T>A 45 ± 12% 33 ± 3%A 67%G 27 ± 3%
c.68-7delT 22 ± 2%# 28 ± 2%A 72%G 32 ± 5%
c.68-7_8delinsAA 49 ± 1% 72 ±1 0 %A 28%G 25 ± 2%
Missense mutations
c.125>G, p.Tyr42Cys 6 ± 1% 47 ± 7%A** 53%G** 3 ± 1%
c.223G>C, p.Ala75Pro 3 ± 1% 50 ± 1%G** 50%C** 5 ± 2%
Nonsense mutations
c.71T>A, p.Leu24X 5 ± 1% 52 ± 2%T** 48%A** 2 ± 1%
c.244A>T, p.Lys82X 11 ± 1% 52 ± 4%A** 48%T** 11 ± 2%
c.250C>T, p.Gln84X 12 ± 1% 57 ± 4%C** 43%T** 10 ± 6%
# RNA from PAXgene, *three RNA samples from PAXgene and seven RNA samples from lymphoblastoid cells, ** heterozygosity was proven with other set of
primer. Values (%) are means of three experiments.
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Page 7 of 12them, of which the proband (III-2), could be tested and
were carriers. The affected mother of the proband could
be considered as an obligate carrier. Added to a non
affected female cousin (32 years old) who tested positive,
the carrier genotype could be established or deduced in
six females. Out of them, 5 had developed breast cancer
at age 37, 41, 47, 48 and 50 (mean age: 44.6), with bilat-
eral breast cancer in one case (II-5). One female carrier
underwent bilateral prophylactic mastectomy at age 32.
Penetrance could be estimated at 50% by age 45 and at
100% by age 50. Histopathological data, when available,
showed grade II or III, oestrogen-receptor (ER) positive
and HER2-negative breast tumours, a phenotype
consistent with BRCA2-associated breast cancers. Thus,
in this family, the Δ3-LR allele segregated well with
affected family members, which is consistent with the
hypothesis that Δ3-LR is a deleterious allele.
Family B-2002 (Figure 4) is a breast/ovarian cancer
family, with four breast cancer cases at 43, 43, 52 and 55
years old (mean age: 48.3) and one ovarian cancer at age
52. Controlateral breast cancer occurred in two patients
(II-1 and II-13). The c.316+3delA mutation of BRCA2
was detected in the proband (II-1) affected with breast
cancer at age 52, controlateral breast cancer at 55, and
also papillary thyroid cancer at age 33. The mother with
ovarian cancer at 52 is an obligate carrier.
E+ E+ E-
breast  ca.
diagn. 48y
breast ca.
diagn. 41y
breast ca. (bilat.)
diagn. 50y
LNH
diagn. 44y
prostate ca.
diagn. 59y
breast ca.
diagn. 37y-53y
cervix ca.
diagn. 42y
breast ca.
diagn. 47y
I
II
III
48y
breast ca.
diagn. 45y
55y 71y 61y 58y 54y 52y
 49y 45y 44y 42y 48y 45y 37y
2 2
33y 32y
E- E-
E-
E+ E+
E+
1 2 3 4 5 6
12 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5
Figure 3 Family pedigree (A-2005) of the patient carrying the BRCA2 Δ3 large rearrangement. Pedigree symbols: black figures: affected
individuals, diagonal slash: deceased individuals; arrow: proband, E: tested for Δ3 large rearrangement, E+: mutation carrier, E-: non carrier, LNH:
Non-Hodgkin lymphoma, ca.: cancer.
E+ E-
breast  ca.
diagn. 52-55y
breast ca.
diagn. 55y
ovarian Ca.
diagn. 52y
II
breast Ca.
79y 81y
 60y 59y 57y 55y 54y 50y 48y
E+
E+
E+ E- E-
E+
E+
breast  ca.
diagn. 43y
E- E- E-
59y
E+
58y
E-
57y
E+
breast  ca.
diagn. 43-53y
breast Ca.
43y 41y 37y 53y
I
III
E+
40y 36y 30y 34y 35y 25y 20y 34y 28y 25y 21y
12 3
1 23 45 6 7 8 91 0 1 1 1 2 13 14
Figure 4 Family pedigree (B-2002) of the patient carrying the BRCA2 c.316+3delA mutation.P e d i g r e es y m b o l s :black figures: affected
individuals; diagonal slash: deceased individuals; arrow: proband, E: tested for c.316+3delA mutation, E+: mutation carrier, E-: non carrier, ca.:
cancer
Muller et al. BMC Medical Genetics 2011, 12:121
http://www.biomedcentral.com/1471-2350/12/121
Page 8 of 12Histopathological features, when available, consisted of
high grade breast tumours, ER and PR positive, HER2
negative. Familial analysis revealed four unaffected female
carriers 30, 34, 59 and 81 years old. Except for one unaf-
fected carrier, who underwent bilateral prophylactic
annexectomy at age 57 (II-11), no risk reducing surgery
was performed among the three other carriers. Pene-
trance could be estimated at 30% by age 45 and 70% by
age 60.
As a whole, segregation analysis indicates a high
breast cancer risk (100% and 70% by age 60) in both
families, and argues in favour with a deleterious effect of
exon 3 skipping in mutation carriers.
The segregation data for the nonsense mutations in
exon 3 that we studied were too limited to allow con-
clusions about penetrance and comparison with the
afore-mentioned mutations. In brief, the individual with
p.Gln84X (c.250C>T) had an ovarian cancer at 56 years-
old and a breast cancer at 59 years-old. Her mother had
a fallopian tube cancer at 62 years-old and a breast can-
cer at 66 and her grand-mother a breast cancer around
62. The individual with p.Lys82X (c.244A>T) had a
breast cancer at 44 years-old and her mother, who also
carries the mutation, a breast cancer at 45 and an ovar-
ian cancer at 65. Her mother’s sister had also a breast
cancer at 45. The individual with p.Leu24X (c.71T>A)
had a breast cancer at 45 years-old and belonged to a
family with several breast cancers in the maternal
branch (mother: 74, aunt: 50, aunt: 40). Her sister is a
carrier and had a bladder cancer at 39. Finally, all car-
riers were affected by breast cancer between 44 and 66
years-old.
Discussion
The Δ3-LR described here has not been reported pre-
viously and is the third reported mutation that leads to
total exon 3 deletion of the BRCA2 gene. The c.277.317-
726delinsCCAT (putative p.Ser98Glu106delinsPro) has
been detected in a Swedish breast/ovarian cancer family
[13]. The c.156_157insAlu has been described in a Por-
tuguese family as an Alu insertion at codon 52 of
BRCA2 [14,15] and is now considered to be a frequent
founder mutation that is detected in nearly one third of
breast/ovarian cancer families from northern/central
Portugal [16,17]. In our large series of 2058 cases that
are non informative for BRCA1-2 point mutation, the
prevalence of BRCA2 large rearrangements (LR) is esti-
mated to be 3% of all BRCA2 deleterious mutations.
This value is lower than the 7% to 11% reported pre-
viously [3,7,18]. In our six pedigrees, there were no male
breast cancer cases, which contrasts with the literature
[7]. Moreover, the low frequency of BRCA2 LR could be
explicable by the lower frequency of Alu sequences in
the genomic locus of BRCA2 in comparison to BRCA1.
Screening for BRCA2 large constitutive rearrangements
should be recommended in comprehensive genetic tests,
especially for families with multiple breast and/or ovar-
ian cancer cases and families with at least one case of
male breast cancer.
There is some debate about the pathogenic effect of
BRCA2 exon 3 alterations due to the particular features
of exon 3 in BRCA2. Exon 3 is in phase in the gene and
is absent in the physiological alternative transcript
(delta3-transcript) that has been detected in normal tis-
sues, and in particular at moderate to low levels in
mammary gland and prostate tissues [4].
We extensively analysed the balance between delta3-
and full-length transcript levels, using different methods
that include allele specific expression and competitive
quantitative PCR by pyrosequencing which avoids misin-
terpretations associated with fragment analysis. We
observed three classes of differential expression of the
delta3-transcript.
We detected low levels of the delta3-transcript in
wild-type RNA, which represent less than 10% of the
total transcript levels, which could be considered to be
constitutive expression of the delta3-transcript. Alterna-
tive splicing is less common for BRCA2 than for
BRCA1. A splice variant lacking exon 12 of BRCA2 has
been detected at higher levels in 33% of breast tumours
compared to matched normal tissues, suggesting that
dysregulated expression of the isoform may contribute
to breast cancer progression [19]. However, recent data
indicate that exon 12 is redundant and its loss may not
have an impact on the disease [20]. We detected low
levels (nearly 10%) of the alternative transcript that
lacks exon 3 BRCA2, using 185 sporadic breast tumours
samples and some head and neck tumours and normal
tissues samples. This constitutive low level of expression
suggests that the delta3-transcript is not involved in
tumorigenesis in sporadic tumours. The physiological
role of this low level of the delta3-transcript remains to
be established.
In the case of the Δ3-LR, genomic deletion of exon 3
results in an increase of the proportion of the delta3-
transcript relative to the full-length transcript, to 40-
50% (by fragment analysis and confirmed by competitive
QPCR). This corresponds to a total loss of exon 3 on
one allele, as expected due to the large rearrangement.
The same result was observed for the sample with the
c.316+3delA mutation that also leads to the loss of exon
3 in the RNA. Moreover, the exclusive expression of
delta3-transcript by the mutated allele, which we
demonstrated by allelic discrimination analysis of the
c.316+3delA mutation that is heterozygous for the c.-26
G>A polymorphism, confirms our results. Our results
are similar to those reported for a mutation in intron 3,
c.316+5 G>C (which was analyzed in a mini-gene
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of which result in total splicing out of exon 3 on the
mutated allele. Consequently, these data, taken together,
support the hypothesis of a pathogenic effect when
there is exclusive synthesis of the delta3-transcript from
one allele. Such functional mRNA splice variants have
been demonstrated for two splice site mutations in
BRCA1 gene, c.212+3A>G and c.135-6T>G. These iso-
forms, that lead to an in frame deletion of exon 5, were
found to be expressed at increased levels in tumour
cells [22].
The hypothesis of a causal effect of exon 3 deletion is
supported by the co-segregation analysis of both families,
with Δ3-LR and c.316+3delA, respectively. Co-segrega-
tion with disease of loss of exon 3, or of total exclusion of
the full-length transcript, is strong, and results in high
penetrance of breast cancer in mutation carriers of both
families. This is also the case for the afore mentioned
mutations, c.316+5G>C [21] found in all affected mem-
bers of two families with breast and breast/ovarian cancer
syndrome (S. Krieger personal communication) and the
founder Portuguese mutation c.156_157insAlu
[14,16,17]. Taken together, these data highlight the clini-
cally relevant effects of the Δ 3 mutant allele and indicate
that it is associated with a significant breast cancer risk.
Our analysis of some intron 2 variants also supports
our contention that loss of exon 3 is relevant for breast
cancer risk. These variants (c.68-7T>A, c.68-7delT, c.68-
7_8delinsAA) have increased levels of the delta3-tran-
scripts, which account for 23 to 30% of the total BRCA2
transcripts. There is an allelic imbalance of 30/70
between full-length transcript and delta3-transcript, that
was shown with the heterozygous c.-26A>G samples.
This proportion suggest that both alleles synthesise the
two transcripts (full-length and delta3), with a slight
imbalance for the mutated allele. However, previous
r e p o r t sa sw e l la sin silico predictions do not favour a
causal effect of the intron 2 mutations. The c.68-7T>A
variant, initially described in one patient with breast and
ovarian cancer in Italy [23], has been widely detected in
France (82 times, UMD-BRCA2 database [24]) some-
times with co-occurrence of two different deleterious
BRCA2 mutations. The c.68-7delT has been previously
described in four endometrial carcinomas with microsa-
tellite instability, one of which had another pathogenic
mutation in BRCA2 [25], and in three colorectal cancers
with microsatellite instability [23]. It was detected once
in our cohort, 54 times in France (UMD-BRCA2 data-
base) [24] with co-occurrence of deleterious BRCA2
mutations, and 4 times in the BIC database [26]. Conse-
quently, the slight increase in the delta3-transcript could
be considered to be neutral in terms of high risk of
breast/ovarian cancer. The relevance of intermediate
levels of delta3-transcription for cancer risk remains to
be established. In fact, in these cases, the loss of the
wild-type allele in tumour tissue would lead to an allele
which produces two forms of protein with and without
exon 3 domain. Thus, we suggest these three distinct
intron 2 mutations should remain unclassified variants
until co-segregation analysis, evaluation of frequency in
control population and/or functional studies are per-
formed, which would clarify whether there is any risk
associated with these mutations.
The results we obtained for the three nonsense muta-
t i o n si ne x o n3t h a tw es t u d i e d ,a n dt h a tw ec o n f i r m e d
by the three transcript analysis methods, have not been
described previously. No significant increase in the
delta3/wild type transcript ratio was detected. This con-
trasts with the Portuguese Alu insertion mutation,
which creates a stop codon 10 nucleotides after the
insertion, but exclusively expresses the delta3-transcript.
In fact, our results suggest that the mutated mRNAs,
that contain the premature stop codon, are not elimi-
nated or destabilized by NMD [27,28]. Indeed, if NMD
were involved, the expression levels of full-length tran-
script from the mutant allele would have been signifi-
cantly decreased, whereas the expression levels of the
delta3-trancript issued from both alleles would probably
not be modified, thus leading to a global increase of the
proportion of the delta3-transcript.
An additional argument towards a pathogenic effect of
Δ3-LR would reside in the impact of the loss of exon 3, at
the functional level, especially in tumours that exclusively
express the transcript due to the genomic deletion on one
allele and loss of the wild type allele. The delta3-transcript
codes for a putative protein that lacks an 83 amino acids
highly conserved bipartite domain, including a primary
activating region (PAR, amino acids 23-60) and an auxili-
ary activating region (AAR, 60-105) [29,30] whose tran-
scriptional activity could be regulated by phosphorylation
through two potential phosphorylation sites [31,32].
Of most relevance, PAR has been shown to interact
with two proteins, EMSY and PALB2 (Partner and Loca-
lizer of BRCA2), which are involved in breast carcino-
genesis. EMSY has endogenous transcriptional repressor
activity and contributes to DNA damage focus forma-
tion [33]. Similar to BRCA2, EMSY relocates to double-
strand break repair sites following DNA damage [34]
and forms a complex with RAD51. EMSY can silence
the transcription activation potential of the BRCA2 pro-
tein region encoded by exon3a n dt h e r e b yn e g a t i v e l y
regulate BRCA2 [33]. Our study shows that delta3-tran-
script expression is not significantly increased in spora-
dic breast tumours, suggesting that other mechanisms
are involved in non-hereditary breast tumorigenesis. To
date, the EMSY gene has been found to be amplified in
7-13% of sporadic breast cancers, 17% of ovarian can-
cers [35] and 13% of pancreatic cancers [36]. Excess of
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could contribute to the tumorigenesis of a substantial
proportion of non-inherited sporadic breast and ovarian
cancers, by silencing BRCA2 [37].
PALB2 is an integral component of the BRCA complex.
It co-localises with BRCA2 in nuclear foci and promotes
its stability in nuclear structures [38], which is essential for
key BRCA2 nuclear caretaker functions. PALB2 also med-
iates the physical interaction of BRCA2 with a carboxy-
terminal fragment of BRCA1 and is required for the coop-
eration between BRCA1 and BRCA2 in the DNA damage
responses [39]. Loss of the exon 3 region could affect the
intranuclear stability of a subpopulation of BRCA2 pro-
teins that is required for DNA repair. This hypothesis is
reinforced by the demonstration that “clinically unclassi-
fied” missense variants, located in exon 3 of BRCA2 (p.
Trp31Arg, p.Trp31Cys, p.Gly25Arg), display complete loss
or reduction of PALB2 binding activity and inefficient
DNA repair [38]. In contrast, the p.Tyr42Cys (Y42C) var-
iant did not differ from wild-type [38]. The p.Tyr42Cys
variant has now been excluded as a disease associated
BRCA2 variant, from in vitro functional studies [40], and
genetic and epidemiologic data, i.e. absence of co- segrega-
tion [41] and high frequency [42 times in France (UMD-
BRCA2)[24] and 141 times in BIC]. The low expression of
delta3-transcripts we observed for this variant is in accor-
dance with these conclusions. Taken together, our data
lead to the hypothesis that disruption of the balance
between BRCA2 transcripts could predispose to disease.
BRCA2 protein, without the exon 3 region, may act as a
dominant negative inhibitor of its transcriptional function,
and could also be modified in its DNA repair activity.
Conclusion
There are strong arguments to suggest that loss of the exon
3 encoded “region” could be a cause of breast cancer pre-
disposition. The exon 3 region is involved in the transcrip-
tional and DNA damage response functions of BRCA2.
Furthermore exclusive expression of the delta3-transcript
co-segregates with the disease. Our study suggests that
exclusive transcript expression from the mutated allele
contributes to high risk breast cancer, whereas moderate to
low delta3-transcript levels are neutral as long as the full-
length transcript is present at a roughly normal level. How-
ever, the question remains open whether low to moderate
levels of the delta3-transcript have an impact on BRCA2
functions and could contribute to increased risk of breast
cancer. Additional analysis of the functional consequences
of loss of exon 3 in the BRCA2 gene are required, particu-
larly for those variants that lead to intermediate delta3-
transcript level. Noteworthy, although the transcript is
deleted for exon 3, the highly conserved and functionally
important amino-terminal BRCA2 region is preserved.
Moreover, when investigating potentially lacking exon 3
mutations, various analysis approaches should be combined
to differentiate their impact on transcript imbalance and
co-segregation studies should be performed systematically
to further support these data.
Additional material
Additional file 1: Schematic figure to explain the principle of
competitive quantitative PCR (C-QPCR). a) pyrograph (right) and
subsequent pyrogram (left) obtained using the two set of primers on
exon 2 and exon 3 (full-length transcript) and on exon 2 and exon 4
(delta3-transcript). b) pyrograms of the C-QPCR showing the three levels
of delta3-transcript (5%, 20%, 46%). c) sensitivity study of the C-QPCR
obtained with a mix of exon2-3 amplicons and exon 2-4 amplicons for a
range of delta3-transcript concentrations (5%, 10%, 25%, 50% 75%, 90%).
On the × axis, the proportion of delta3-transcripts (exon2-4) in the mix, y
axis, pyrosequencing results in % of delta3-transcripts from the C-QPCR.
Additional file 2: Illustration of the consequences on proportion of
delta3-transcripts and on allelic discrimination, of the three cases:
wild-type, moderate (c.68-7T>A) and exclusive (c.316+3delA and exon 3
deletion) expression of exon 3 spliced transcripts. The A/B allelic
discrimination panel gives the theoretical percentages of the allele
depending on the position of primers that specifically dose the total, the
delta3- or the full-length transcripts.
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